Literature DB >> 18248

Selectivity of blocking agents for pre-and postsynaptic alpha-adrenoceptors.

J C Doxey, C F Smith, J M Walker.   

Abstract

1. Low frequency (0.1 Hz) electrical stimulation of the rat isolated vas deferens produced regular contractions that were inhibited by low concentrations of clonidine. 2. The inhibition of the vas deferens produced by clonidine was presynaptic in origin and involved alpha-adrenoceptors. 3. Presynaptic alpha-adrenoceptor antagonist activity was assessed by studying the effects of increasing concentrations of the antagonists on cumulative clonidine dose-response curves on the stimulated vas deferens. 4. Postsynaptic alpha-adrenoceptor antagonist activity was assessed by comparison of control cumulative noradrenaline dose-response curves with those in the presence of increasing concentrations of antagonists in the rat anococcygeus muscle. 5. The results indicate that yohimbine and phentolamine are more potent in blocking presynaptic than postsynaptic alpha-adrenoceptors. Phenoxybenzamine and prazosin block postsynaptic alpha-adrenoceptors preferentially. 6. The findings support the view that presynaptic and postsynaptic alpha-adrenoceptors differ in their sensitivity to alpha-adrenoceptor antagonists.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 18248      PMCID: PMC1667189          DOI: 10.1111/j.1476-5381.1977.tb16752.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  11 in total

1.  Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters.

Authors:  J M VAN ROSSUM
Journal:  Arch Int Pharmacodyn Ther       Date:  1963

2.  Cardiovascular effects of prazosin in normotensive and genetically hypertensive rats.

Authors:  A J Wood; E L Phelan; F O Simpson
Journal:  Clin Exp Pharmacol Physiol       Date:  1975 Jul-Aug       Impact factor: 2.557

3.  Pre- and postsynaptic components in effect of drugs with alpha adrenoceptor affinity.

Authors:  K Starke; T Endo; H D Taube
Journal:  Nature       Date:  1975-04-03       Impact factor: 49.962

4.  Preferential blockade of presynaptic alpha-adrenoceptors by yohimbine.

Authors:  K Starke; E Borowski; T Endo
Journal:  Eur J Pharmacol       Date:  1975-12       Impact factor: 4.432

Review 5.  Presynaptic regulation of catecholamine release.

Authors:  S Z Langer
Journal:  Biochem Pharmacol       Date:  1974-07-01       Impact factor: 5.858

6.  Negative feed-back regulation of noradrenaline release by nerve stimulation in the perfused cat's spleen: differences in potency of phenoxybenzamine in blocking the pre- and post-synaptic adrenergic receptors.

Authors:  M L Dubocovich; S Z Langer
Journal:  J Physiol       Date:  1974-03       Impact factor: 5.182

7.  Evidence against adrenergic motor transmission in the guinea-pig vas deferens.

Authors:  N Ambache; M A Zar
Journal:  J Physiol       Date:  1971-07       Impact factor: 5.182

8.  Alpha sympathomimetic inhibition of adrenergic and cholinergic transmission in the rabbit heart.

Authors:  K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

9.  The rat anococcygeus; a new, densely innervated smooth muscle preparation.

Authors:  J S Gillespie
Journal:  Br J Pharmacol       Date:  1971-10       Impact factor: 8.739

10.  Comparison of the effects of clonidine on pre- and postsynaptic adrenoceptors in the rabbit pulmonary artery. Alpha-sympathomimetic inhibition of Neurogenic vasoconstriction.

Authors:  K Starke; H Montel; W Gayk; R Merker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

View more
  108 in total

1.  Involvement of presynaptic alpha-adrenoceptors in the cardiovascular and sedative effects of FLA-136.

Authors:  P B Timmermans; E Lam; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-03       Impact factor: 3.000

2.  Hyperpolarizing 'alpha 2'-adrenoceptors in rat sympathetic ganglia.

Authors:  D A Brown; M P Caulfield
Journal:  Br J Pharmacol       Date:  1979-03       Impact factor: 8.739

3.  Comparison of pre-junctional alpha-adrenoceptors at the neuromuscular junction with vascular post-junctional alpha-receptors in cat skeletal muscle.

Authors:  E Malta; G A McPherson; C Raper
Journal:  Br J Pharmacol       Date:  1979-02       Impact factor: 8.739

4.  Do both adrenaline and noradrenaline stimulate cardiac alpha-adrenoceptors to induce positive inotropy of rat atria?

Authors:  K L Williamson; K J Broadley
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

5.  Prazosin depression of baroreflex function in hypertensive man.

Authors:  E H Sasso; D T O'Connor
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Study of the mechanism of the relaxant action of (+)-glaucine in rat vas deferens.

Authors:  F Orallo; A Fernández Alzueta; M I Loza; N Vivas; A Badía; M Campos; M A Honrubia; M I Cadavid
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

7.  The role of catecholamines in the production of ischaemia-induced ventricular arrhythmias in the rat in vivo and in vitro.

Authors:  A Daugherty; K N Frayn; W S Redfern; B Woodward
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

8.  alpha 1-Adrenoceptor subtype mediating contraction of the smooth muscle in the lower urinary tract and prostate of rabbits.

Authors:  K Honda; A Miyata-Osawa; T Takenaka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-07       Impact factor: 3.000

9.  The distribution of adrenoceptors and other drug receptors between the two ends of the rat vas deferens as revealed by selective agonists and antagonists.

Authors:  A MacDonald; J C McGrath
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

10.  Evidence in favour of a selective alpha 1-adrenoceptor blocking action of WB 4101 in vivo.

Authors:  G M Drew
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.